XELJANZ XR (tofacitinib) extended-release tablets
XELJANZ/XELJANZ XR is a brand-name prescription drug that’s FDA-approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. XELJANZ XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012
Home | (tofacitinib) extended-release tablets
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Overseas Patient/ Export inquires.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
XELJANZ XR (tofacitinib) extended-release tablets
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
XELJANZ/XELJANZ XR is a prescription medicine called a Janus kinase (JAK) inhibitor.
XELJANZ/XELJANZ XR is used to treat adults with moderately to severely active rheumatoid arthritis in
whom methotrexate did not work well.
XELJANZ/XELJANZ XR is used to treat adults with active psoriatic arthritis in which methotrexate or other
similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well.
XELJANZ is used to treat adults with moderately to severely active ulcerative colitis.
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.
XELJANZ/XELJANZ XR is not recommended for people with severe liver
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.
Tofacitinib citrate is approved for medical use in the United States with an indication “to treat adults with moderately to severely active rheumatoid arthritis.” In the European Union, in combination with methotrexate, tofacitinib citrate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA).
In May 2018, the FDA approved tofacitinib citrate “for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis.” Tofacitinib citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis.
Drug (Brand / Generic): XELJANZ XR / tofacitinib tablets
Current Indications: rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
Marketed by:: National Institutes of Health and Pfizer.
Approval Date: 2012
Available as (Form & Strength): XELJANZ Tablets: 5 mg, 10 mg tofacitinib, XELJANZ XR Tablets: 11 mg tofacitinib.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier / importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “XELJANZ XR (tofacitinib) extended-release tablets”.
Confirmation of the order for XELJANZ XR (tofacitinib) extended-release tablets will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand XELJANZ XR (tofacitinib) extended-release tablets. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to XELJANZ XR (tofacitinib) extended-release tablets, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for XELJANZ XR (tofacitinib) extended-release tablets price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.